1. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study. Issue 33 (20th November 2022) Authors: Platzbecker, Uwe; Götze, Katharina S.; Kiewe, Philipp; Germing, Ulrich; Mayer, Karin; Radsak, Markus; Wolff, Thomas; Chromik, Joerg; Sockel, Katja; Oelschlägel, Uta; Haase, Detlef; Illmer, Thomas; Al-Ali, Haifa Kathrin; Silling, Gerda; Reynolds, Joseph G.; Zhang, Xiaosha; Attie, Kenneth M.; Shett... Journal: Journal of clinical oncology Issue: Volume 40:Issue 33(2022) Page Start: 3800 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia. (December 2022) Authors: Piga, Antonio; Longo, Filomena; Gamberini, Maria Rita; Voskaridou, Ersi; Ricchi, Paolo; Caruso, Vincenzo; Pietrangelo, Antonello; Zhang, Xiaosha; Shetty, Jeevan K.; Attie, Kenneth M.; Tartaglione, Immacolata Journal: Therapeutic advances in hematology Issue: Volume 13(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗